Autres langues Cogent Biosciences, Inc.

Actions

COGT

US19240Q2012

Recherche biotechnologique et médicale

Marché Fermé - 22:00:00 11/09/2026 Varia. 5j. Varia. 1 janv.
33,41 USD -1,97% Graphique intraday de Cogent Biosciences, Inc. -3,88% -5,94%

Autres langues

02/09 Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
31/08 Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
10/08 Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08 Cogent Biosciences Q2 Loss Widens
10/08 Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss
10/08 Cogent Biosciences : August 10, 2026
10/08 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
30/06 Cogent Biosciences Submits New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis
30/06 Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment
30/06 Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 2000 Value Benchmark
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Index
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Value Benchmark
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000 Value Benchmark
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Index
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Small Cap Comp Value Benchmark
29/06 Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 2500 Value Benchmark
12/06 Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
12/06 Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
12/06 Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
12/06 Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology
12/06 Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
Aucun résultat pour cette recherche
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT